Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine if radon mitigation can improve asthma
We will conduct a randomized, double-blind, sham controlled trial to investigate the efficacy of radon mitigation in the homes of susceptible individuals to provide evidence for health benefits by improving indoor air quality. The trial will include 180 children with asthma. We will install a standard radon specific mitigation system in the participant's home. Health outcomes will be followed over 48 weeks to determine the outcomes of the intervention versus inactive (sham) control.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Radon Mitigation | Active Comparator | Active radon mitigation system |
|
| Inactive radon mitigation system control( sham) | Sham Comparator | Inactive radon mitigation system looks and sounds like active but doesn't reduce radon ( sham) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| radon mitigation system | Other | standard radon mitigation system used to reduce radon in homes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Asthma symptoms | Number of Days With Asthma Symptoms | past 2 weeks |
Not provided
Not provided
Use of an asthma medication during the prior 12 months, report of asthma symptoms over the prior 12 months (wheezing/whistling in the chest)(3)
OR
One or more asthma-related hospitalization, emergency room visit
OR
Unscheduled clinic or urgent care facility visit resulting in a burst of systemic steroids (3 days or more of prednisone or equivalent; 1 or more doses of dexamethasone) in the previous 12 months
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wanda Phipatanakul | Contact | 857-218-5336 | Asthma@childrens.harvard.edu |
| Name | Affiliation | Role |
|---|---|---|
| Wanda Phipatanakul | Boston Children's Hospital | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C005703 | salicylhydroxamic acid |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sham (No Treatment) | Other | inactive radon mitigation system |
|
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |